Patents by Inventor Lourdes J. Cruz
Lourdes J. Cruz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7368432Abstract: The invention relates to relatively short conotoxin peptides, about 10-20 residues in length as described herein, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. These conotoxin peptides have analgesic activity and are thus useful for treating or preventing pain.Type: GrantFiled: July 19, 2004Date of Patent: May 6, 2008Assignees: Xenome, Ltd., Cognetix, Inc.Inventors: J. Michael McIntosh, Baldomero M. Olivera, Lourdes J. Cruz, Gloria P. Corpuz, Robert M. Jones, James E. Garrett
-
Publication number: 20040192886Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: April 21, 2004Publication date: September 30, 2004Applicants: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Maren Watkins, Lourdes J. Cruz, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier, Gregory S. Shen, John D. Wagstaff
-
Patent number: 6767896Abstract: The invention relates to relatively short conotoxin peptides, about 10-20 residues in length as described herein, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. These conotoxin peptides have analgesic activity and are thus useful for treating or preventing pain.Type: GrantFiled: May 26, 2000Date of Patent: July 27, 2004Assignees: Cognetix, Inc., University of Utah Research FoundationInventors: J. Michael McIntosh, Baldomero M. Olivera, Lourdes J. Cruz, Gloria P. Corpuz, Robert M. Jones, James E. Garrett
-
Patent number: 6727226Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: GrantFiled: July 23, 2001Date of Patent: April 27, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Lourdes J. Cruz, Robert M. Jones, G. Edward Cartier, John D. Wagstaff
-
Patent number: 6696408Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: GrantFiled: June 29, 2000Date of Patent: February 24, 2004Assignees: University of Utah Research Foundation, Cognetix, Inc.Inventors: A. Grey Craig, David Griffen, Baldomero M. Olivera, Maren Watkins, David R. Hillyard, Julita Imperial, Lourdes J. Cruz, John D. Wagstaff, Richard T. Layer, Robert M. Jones, R. Tyler McCabe
-
Publication number: 20030194729Abstract: The present invention is directed to conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues. The contantokins are useful for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.Type: ApplicationFiled: February 4, 2003Publication date: October 16, 2003Inventors: Fe C. Abogadie, Lourdes J. Cruz, Baldomero M. Olivera, Craig Walker, Clark Colledge, David R. Hillyard, Elsie Jimenez
-
Patent number: 6624288Abstract: This invention relates to relatively short peptides about 25-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogs to the naturally available peptides, and which include three cyclizing disulfide linkages and one or more &ggr;-carboxyglutamate residues.Type: GrantFiled: December 15, 1998Date of Patent: September 23, 2003Assignees: Cognetix, Inc., University of Utah Research FoundationInventors: Michael Fainzilber, Karel S. Kits, Alma L. Burlingame, Baldomero M. Olivera, Craig Walker, Maren Watkins, Reshma Shetty, Lourdes J. Cruz, Julita Imperial, Clark Colledge
-
Publication number: 20030166560Abstract: The present invention is directed to P-superfamily conopeptides, to DNA encoding precursors of the P-superfamily conopeptides and to the precursor peptides.Type: ApplicationFiled: January 30, 2003Publication date: September 4, 2003Inventors: David Hooper, James E. Garrett, Gloria P. Corpuz, Lourdes J. Cruz, Baldomero M. Olivera, J. Michael McIntosh, Robert M. Jones
-
Publication number: 20030109670Abstract: The present invention is directed to conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, voltage-gated ligand channels and/or receptors. The invention is further directed to nucleic acid sequences encoding the conotoxin peptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: February 11, 2002Publication date: June 12, 2003Applicant: University of Utah Research FoundationInventors: Baldomero M. Olivera, J. Michael McIntosh, Maren Watkins, James E. Garrett, Lourdes J. Cruz, Michelle Grilley, Robert A. Schoenfeld, Craig S. Walker, Reshma P. Shetty, Robert M. Jones
-
Publication number: 20030050234Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: July 23, 2001Publication date: March 13, 2003Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Maren Watkins, Lourdes J. Cruz, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier, Gregory S. Shen, John D. Wagstaff
-
Patent number: 6515103Abstract: The present invention is directed to conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues. The conantokins are useful for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.Type: GrantFiled: May 11, 2000Date of Patent: February 4, 2003Assignees: University of Utah Research Foundation, Cognetix, Inc., Salk InstituteInventors: Fe C. Abogadie, Lourdes J. Cruz, Baldomero M. Olivera, Craig Walker, Clark Colledge, David R. Hillyard, Elsie Jimenez, Richard T. Layer, Li-Ming Zhou, Gregory S. Shen, R. Tyler McCabe, Jean E. Rivier
-
Patent number: 6489298Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: GrantFiled: June 29, 2000Date of Patent: December 3, 2002Assignee: Cognetix, Inc.Inventors: A. Grey Craig, David Griffen, Baldomero M. Olivera, Maren Watkins, David R. Hillyard, Julita Imperial, Lourdes J. Cruz, John D. Wagstaff, Richard T. Layer, Robert M. Jones, R. Tyler McCabe
-
Patent number: 6369193Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: GrantFiled: October 19, 1999Date of Patent: April 9, 2002Assignees: University of Utah Research Foundation, The Salk Institute for Biological StudiesInventors: A. Grey Craig, David Griffen, Baldomero M. Olivera, Maren Watkins, David R. Hillyard, Julita Imperial, Lourdes J. Cruz
-
Patent number: 6344551Abstract: The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.Type: GrantFiled: June 29, 2000Date of Patent: February 5, 2002Assignee: University of Utah Research FoundationInventors: A. Grey Craig, David Griffin, Baldomero M. Olivera, Maren Watkins, David R. Hillyard, Julita Imperial, Lourdes J. Cruz, John D. Wagstaff, Richard T. Layer, Robert M. Jones, R. Tyler McCabe
-
Patent number: 6153738Abstract: The present invention is directed to contryphan peptides having 6-12 amino acids, preferably including one or more D-tryptophan or D-leucine residues. The peptides of the present invention are generically termed "contryphans," although the D-leucine containing contryphans are sometimes referred to as leu-contryphans. More specifically, the present invention is directed to contryphan peptides having the general formula Xaa.sub.1 -Cys-Xaa.sub.2 -Xaa.sub.3 -Xaa.sub.4 -Pro-Xaa.sub.5 -Cys (SEQ ID NO:1), wherein Xaa.sub.1 is any amino acid or des-Xaa.sub.1, Xaa.sub.2 is Pro, 4-trans-hydroxyproline or Val, Xaa.sub.3 is D-Trp, L-Trp, D-Leu or L-Leu, preferably D-Trp or D-Leu, Xaa.sub.4 is any amino acid and Xaa.sub.5 is Trp or Tyr. When the peptide contains Xaa.sub.1, it is preferably Gly, Glu, or Lys, most preferably Gly. When Xaa.sub.3 is D- or L-Trp, Xaa.sub.2 is preferably Pro or 4-trans-hydroxyproline. When Xaa.sub.3 is D- or L-Leu, Xaa.sub.2 is preferably Val.Type: GrantFiled: December 21, 1999Date of Patent: November 28, 2000Assignee: University of Utah Research FoundationInventors: Richard Jacobsen, Elsie Jimenez, Lourdes J. Cruz, Baldomero M. Olivera, William R. Gray, Michelle Grilley, Maren Watkins, David R. Hillyard
-
Patent number: 6077934Abstract: The present invention is directed to contryphan peptides having 6-12 amino acids, preferably including one or more D-tryptophan or D-leucine residues. The peptides of the present invention are generically termed "contryphans," although the D-leucine containing contryphans are sometimes referred to as leu-contryphans. More specifically, the present invention is directed to contryphan peptides having the general formula Xaa.sub.1 -Cys-Xaa.sub.2 -Xaa.sub.3 -Xaa.sub.4 -Pro-Xaa.sub.5 -Cys (SEQ ID NO:1), wherein Xaa.sub.1, is any amino acid or des-Xaa.sub.1, Xaa.sub.2 is Pro, 4-trans-hydroxyproline or Val, Xaa.sub.3 is D-Trp, L-Trp, D-Leu or L-Leu, preferably D-Trp or D-Leu, Xaa.sub.4 is any amino acid and Xaa.sub.5 is Trp or Tyr. When the peptide contains Xaa.sub.1, it is preferably Gly, Glu, or Lys, most preferably Gly. When Xaa.sub.3 is D- or L-Trp, Xaa.sub.2 is preferably Pro or 4-trans-hydroxyproline. When Xaa.sub.3 is D- or L-Leu, Xaa.sub.2 is preferably Val.Type: GrantFiled: April 16, 1998Date of Patent: June 20, 2000Assignee: University of Utah Research FoundationInventors: Richard Jacobsen, Elsie Jimenez, Lourdes J. Cruz, Baldomero M. Olivera, William R. Gray, Michelle Grilley, Maren Watkins, David R. Hillyard
-
Patent number: 5889147Abstract: The present invention is directed to conopeptides having 6-45 amino acids, including one or more bromo-tryptophan residues. More specifically, the present invention is directed to conopeptides having the general formula: R-(Cys).sub.n -R.sup.1 -B-R.sup.2 -Cys-R.sup.3, wherein R is a peptide chain of 0-24 amino acids, R.sup.1 is a peptide chain of 0 to 31 amino acids, R.sup.2 is a peptide chain of 0-29 amino acids, R.sup.3 is a peptide chain of 0 to 26 amino acids, B is 6-bromo-tryptophan, n is 0 or 1 and the total length of the conopeptide is from about 6 to about 45 amino acids. The invention also includes pharmaceutically acceptable salts of the conopeptides. These bromo-tryptophan containing conopeptides invention are useful as antihelminthic agents, anti-vomiting agents, sleep-inducing agents, adjuncts to anesthesia, anticonvulsant or neuroprotective agents.Type: GrantFiled: January 17, 1997Date of Patent: March 30, 1999Assignees: University of Utah Research Foundation, Salk Institute, Regents of the University of CaliforniaInventors: Lourdes J. Cruz, Baldomero M. Olivera, J. Michael McIntosh, Elsie Jimenez, A. Grey Craig, Jean A. Rivier, David Julius, Laura England
-
Patent number: 5700778Abstract: Substantially pure conotoxins are provided which inhibit synaptic transmissions at the neuromuscular junctions and which are useful both in vivo and in assays because they specifically target particular receptors, such as the acetylcholine receptor, and ion channels. The peptides are of such length that they can be made by chemical synthesis. They also may be made using recombinant DNA techniques, and the DNA encoding such conotoxins having pesticidal properties can be incorporated as plant defense genes into plant species of interest.Type: GrantFiled: June 2, 1995Date of Patent: December 23, 1997Assignees: The Salk Institute for Biological Studies, University of Utah Research FoundationInventors: Baldomero M. Olivera, Jean E.F. Rivier, Lourdes J. Cruz, Fe Abogadie, Chris E. Hopkins, John Dykert, Josep L. Torres
-
Patent number: 5670622Abstract: The invention is directed to a new .mu.-conotoxin named GIIIA. .mu.-Conotoxin PIIIA consists of 22 amino residues and is found in the Eastern Pacific fish-hunting species Conus purpurascens. This conotoxin is a new Na.sup.+ channel blocker and can be used to resolve tetrodotoxin-sensitive sodium channels into three categories: 1) sensitive to .mu.-PIIIA and .mu.-conotoxin GIIIA; 2) sensitive to .mu.-PIIIA but not to .mu.-GIIIA; and 3) sensitive to neither of these two .mu.-conotoxins. In rat brain, binding competition studies between the two .mu.-conotoxins and saxitoxin suggest at least three pharmacologically distinguishable binding sites. Thus, .mu.-conotoxin PIIIA should be a key tool for distinguishing among different sodium channel subtypes.Type: GrantFiled: February 15, 1996Date of Patent: September 23, 1997Assignee: University of Utah Research FoundationInventors: Ki-Joon Shon, Doju Yoshikami, Maren Marsh, Lourdes J. Cruz, David R. Hillyard, Baldomero M. Olivera
-
Patent number: RE39240Abstract: Substantially pure conotoxins are provided which inhibit synaptic transmissions at the neuromuscular junctions and which are useful both in vivo and in assays because they specifically target particular receptors, such as the acetyl-choline receptor, and ion channels. The peptides are of such length that they can be made by chemical synthesis. They also may be made using recombinant DNA techniques, and the DNA encoding such conotoxins having pesticidal properties can be incorporated as plant defense genes into plant species of interest.Type: GrantFiled: December 22, 1999Date of Patent: August 15, 2006Assignees: University of Utah Research Foundation, The Salk Institute for Biological StudiesInventors: Baldomero M. Olivera, Jean E. F. Rivier, Lourdes J. Cruz, Fe Abogadie, Chris E. Hopkins, John Dykert, Josep L. Torres